title: Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
authors.forename: S
authors.initials: S
authors.lastname: Di Cosimo
authors.forename: G
authors.initials: G
authors.lastname: Ferretti
authors.forename: P
authors.initials: P
authors.lastname: Papaldo
authors.forename: P
authors.initials: P
authors.lastname: Carlini
authors.forename: A
authors.initials: A
authors.lastname: Fabi
authors.forename: E M
authors.initials: EM
authors.lastname: Ruggeri
authors.forename: A
authors.initials: A
authors.lastname: Alimonti
authors.forename: C
authors.initials: C
authors.lastname: Nardoni
authors.forename: F
authors.initials: F
authors.lastname: Cognetti
mesh_terms: D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D012307:Risk Factors
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D003520:Cyclophosphamide